Despite this setback, Vertex’s zimislecel program for T1D is progressing positively, with plans for global regulatory submissions by 2026. Additionally, Vertex’s non-opioid pain medication ...

“NOT GOOD” FOR BIOTECH SECTOR: RBC Capit Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development ...

“NOT GOOD” FOR BIOTECH SECTOR: RBC Capit Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development ...

Despite this setback, Vertex’s zimislecel program for T1D is progressing positively, with plans for global regulatory submissions by 2026. Additionally, Vertex’s non-opioid pain medication, Journavx, ...